C Xiao1, Y Gong2, E Y Han3, A M Gonzalez-Angulo4, N Sneige3. 1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China. 2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: yungong@mdanderson.org. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Departments of Breast Medical Oncology; Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Abstract
BACKGROUND: To date, the stability of human epidermal growth factor receptor 2 (HER2)-positive primary breast carcinomas during disease progression and the role of intervening trastuzumab treatment in the loss of HER2-positive status in paired metastases remain under-investigated. MATERIALS AND METHODS: Sixty-six patients with HER2-positive primary carcinoma and paired metastasis were evaluated. We examined the overall agreement of the HER2 status and compared the status agreement between 38 trastuzumab-treated patients and 28 trastuzumab-naive control patients. The impact of chemotherapy, endocrine therapy, metastatic site (locoregional or distant), and time to relapse (≥5 or <5 years) on the HER2 status change was assessed. RESULTS: Fifty-six (84.9%) patients had HER2 status agreement between paired tumors; 10 patients had HER2-positive-to-negative conversion. The agreement rate in the trastuzumab-treated group and in the control group was comparable (86.8% versus 82.1%) (P = 0.858). Chemotherapy, endocrine therapy, metastatic site, and time to relapse did not significantly affect HER2 stability in either group. In the discordant tumor pairs, variations in testing methods and borderline scores were common. CONCLUSIONS: HER2-positive status remained unchanged in most paired metastases. Loss of HER2-positive status did not seem to be affected by trastuzumab treatment. Differences in testing and interpretation may account for the discordance in some cases.
BACKGROUND: To date, the stability of humanepidermal growth factor receptor 2 (HER2)-positive primary breast carcinomas during disease progression and the role of intervening trastuzumab treatment in the loss of HER2-positive status in paired metastases remain under-investigated. MATERIALS AND METHODS: Sixty-six patients with HER2-positive primary carcinoma and paired metastasis were evaluated. We examined the overall agreement of the HER2 status and compared the status agreement between 38 trastuzumab-treated patients and 28 trastuzumab-naive control patients. The impact of chemotherapy, endocrine therapy, metastatic site (locoregional or distant), and time to relapse (≥5 or <5 years) on the HER2 status change was assessed. RESULTS: Fifty-six (84.9%) patients had HER2 status agreement between paired tumors; 10 patients had HER2-positive-to-negative conversion. The agreement rate in the trastuzumab-treated group and in the control group was comparable (86.8% versus 82.1%) (P = 0.858). Chemotherapy, endocrine therapy, metastatic site, and time to relapse did not significantly affect HER2 stability in either group. In the discordant tumor pairs, variations in testing methods and borderline scores were common. CONCLUSIONS:HER2-positive status remained unchanged in most paired metastases. Loss of HER2-positive status did not seem to be affected by trastuzumab treatment. Differences in testing and interpretation may account for the discordance in some cases.
Authors: Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge Journal: Mol Cancer Ther Date: 2019-04-08 Impact factor: 6.261
Authors: Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton Journal: Nat Rev Clin Oncol Date: 2014-11-25 Impact factor: 66.675
Authors: Stephanie A Kazane; Devin Sok; Edward H Cho; Maria Loressa Uson; Peter Kuhn; Peter G Schultz; Vaughn V Smider Journal: Proc Natl Acad Sci U S A Date: 2012-02-15 Impact factor: 11.205
Authors: Beyhan Ataseven; Daniela Gologan; Angela Gunesch; Victoria Kehl; Bernhard Hoegel; Michaela Beer; Wolfgang Eiermann Journal: Breast Care (Basel) Date: 2012-12 Impact factor: 2.860
Authors: W Hanna; P Barnes; R Berendt; M Chang; A Magliocco; A M Mulligan; H Rees; N Miller; L Elavathil; B Gilks; N Pettigrew; D Pilavdzic; S Sengupta Journal: Curr Oncol Date: 2012-12 Impact factor: 3.677
Authors: Renata Duchnowska; Rafał Dziadziuszko; Tomasz Trojanowski; Tomasz Mandat; Waldemar Och; Bogumiła Czartoryska-Arłukowicz; Barbara Radecka; Wojciech Olszewski; Franciszek Szubstarski; Wojciech Kozłowski; Bożena Jarosz; Wojciech Rogowski; Anna Kowalczyk; Janusz Limon; Wojciech Biernat; Jacek Jassem Journal: Breast Cancer Res Date: 2012-08-16 Impact factor: 6.466
Authors: Jorge A Carrasquillo; Patrick G Morris; John L Humm; Peter M Smith-Jones; Volkan Beylergil; Timothy Akhurst; Joseph A O'donoghue; Shutian Ruan; Shanu Modi; Clifford A Hudis; Steven M Larson Journal: Q J Nucl Med Mol Imaging Date: 2016-05-12 Impact factor: 1.560
Authors: M E Menezes; S K Das; I Minn; L Emdad; X-Y Wang; D Sarkar; M G Pomper; P B Fisher Journal: Adv Cancer Res Date: 2016-08-17 Impact factor: 6.242